Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.
Global pharma major Lupin Limited announced the launch of Sildenafil for Oral Suspension, 10 mg/mL, having received an approval from the United States Food and Drug Administration (FDA).
Sildenafil for Oral Suspension, 10 mg/mL, is a generic equivalent of Revatio® for Oral Suspension, 10 mg/mL of Viatris Specialty LLC.
Sildenafil for Oral Suspension (RLD Revatio®) had estimated annual sales of USD 64 million in the U.S. (IQVIA MAT July 2022).